Scleroderma Therapeutics Market

Scleroderma is an autoimmune, rheumatic, and chronic disease that affects the body by hardening connective tissue. Therapies include immunosuppressive drugs and, in some cases, glucocorticoids, and it is expected to the development of targeted biologics and small molecule combination therapies.

Scleroderma Therapeutics Market contains market size and forecasts of Scleroderma Therapeutics in Global, including the following market information:

Global Scleroderma Therapeutics Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global top five companies in 2021 (%)

The global Scleroderma Therapeutics market was valued at 1442.9 million in 2021 and is projected to reach US$ 1805.5 million by 2028, at a CAGR of 3.3% during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Immunosuppressors Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Scleroderma Therapeutics include F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Celgene Corporation, Argentis Pharmaceuticals, LLC, Bayer AG, Boehringer Ingelheim International GmbH, Akashi Therapeutics, Prometic Life Sciences, Inc. and Emerald Health Pharmaceuticals, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Scleroderma Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Scleroderma Therapeutics Market, by Type, 2017-2022, 2023-2028 ($ millions)

Global Scleroderma Therapeutics Market Segment Percentages, by Type, 2021 (%)

• Immunosuppressors
• Phosphodiesterase 5 Inhibitors - PHA
• Endothelin Receptor Antagonists
• Prostacyclin Analogues
• Calcium Channel Blockers
• Analgesics
• Others

Global Scleroderma Therapeutics Market, by Application, 2017-2022, 2023-2028 ($ millions)

Global Scleroderma Therapeutics Market Segment Percentages, by Application, 2021 (%)

• Systemic
• Localized

Global Scleroderma Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)

Global Scleroderma Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Scleroderma Therapeutics revenues in global market, 2017-2022 (estimated), ($ millions)
• Key companies Scleroderma Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb Company
• Celgene Corporation
• Argentis Pharmaceuticals, LLC
• Bayer AG
• Boehringer Ingelheim International GmbH
• Akashi Therapeutics
• Prometic Life Sciences, Inc.
• Emerald Health Pharmaceuticals
• Kadmon Holdings, Inc.
• Seattle Genetics, Inc.
• Cytori Therapeutics, Inc.
• Fibrocell Science, Inc.
• Chemomab
• Corbus Pharmaceuticals Holdings, Inc.
• Genkyotex